Bridgeworth’s Celgene Corp CELG Stock Holding History

Bridgeworth’s Portfolio CELG Stock Details CELG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-668	Closed	-$53K	–	657
2018 Q2	$53K	Buy	+668	New	+$55.5K	0.02%	278

Other funds holding CELG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Edgewood Management Greenwich, Connecticut $15.5B AUM 9.67% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bridgeworth's CELG Position: Q3 2018 in Review

Bridgeworth sold out of Celgene Corp (CELG) in Q3 2018, closing a stake of 668 shares — an estimated $53K sold.

Bridgeworth first reported a position in CELG in Q2 2018 and held it in 1 quarter. The position peaked at $53K in Q2 2018. 1,364 funds tracked by Wall St. Rank hold CELG as of Q3 2018.

Bridgeworth reported no remaining Celgene Corp position as of Q3 2018 after selling out during the quarter.
Bridgeworth sold 668 Celgene Corp shares in Q3 2018, an estimated $53K.
Bridgeworth first reported a position in Celgene Corp in Q2 2018 and held it in 1 quarter.
Bridgeworth's Celgene Corp position peaked at $53K in Q2 2018.
1,364 funds tracked by Wall St. Rank held Celgene Corp as of Q3 2018.

Based on Bridgeworth's 13F filing for Q3 2018, filed 13 Nov 2018.